Type II (non-insulin-dependent) diabetes mellitus is a clinical syndrome that is likely to result from a complex interaction between environmental and genetic factors. Recently, several monogenic forms of Type II diabetes have been identified [1±3]. Furthermore, genetic variation in the gene encoding calpain-10 is associated with late-onset Type II diabetes among Mexican-Americans [4] and altered glucose metabolism among Pima Indians [5] . Other genetic components of the more common form of late-onset Type II diabetes among Caucasian subjects are not known. The sulphonylurea receptor (SUR1) is a subunit of the pancreatic beta cell ATP-sensitive potassium channel (K ATP channel) [6, 7] . This channel consists of two subunits: the sulphonylurea receptor (SUR1), which belongs to the ATP-binding cassette superfamily, and the inward rectifier K + channel member KIR6.2. Because this protein complex is a key com- Diabetologia (2001) 
ponent in the regulation of insulin secretion in response to glucose or tolbutamide, the SUR1 gene has been considered a plausible candidate gene for Type II diabetes.
Recent studies in Mexican-Americans and Japanese with highly polymorphic DNA markers near the SUR1 gene located at chromosome 11p15.1 did not show evidence for a linkage of the SUR1 locus with Type II diabetes [8, 9] . In contrast, evidence for linkage of the plasma glucose concentration 2 h after oral glucose administration was shown with markers near the SUR1 locus in Mexican-American families ascertained on a Type II diabetic proband [10] . Furthermore, screening of the coding region and intronexon boundaries of the SUR1 gene revealed several polymorphisms [11, 12] . Two polymorphisms, a silent exon 18 Thr759Thr variant and a c®t intron variant in position ±3 of the exon 16 splice acceptor site have been reported to be associated with Type II diabetes or a prediabetic phenotype either alone or in combination [11±17] . Also, a silent variant in exon 31 of the SUR1 gene (AGG®AGA, Arg1273Arg) is associated with hyperinsulinaemia in non-diabetic Mexican-Americans [18] or with Type II diabetes in French Caucasians [19] . In aggregate, association or linkage to diabetes or associated phenotypes have been identified in at least nine independent studies [10±19]. However, none of the sequence variants analysed have been reported to be functional and are therefore likely to be linked to mutations which alter the function or the expression of the gene. It is well known that the control of gene function is not limited to the coding regions. It is conceivable that intronic mutations alter RNA splicing creating variant exons and thus variant SUR1 protein. It is also possible that promoter variants, or even regions as far away as 100 kb could alter SUR1 expression.
Recently, the promoter of the SUR1 gene was cloned [20, 21] . Studies using transfection of promoter constructs in cultured cells have shown that both mouse and human SUR1 5'flanking regions are highly GC-rich, lack a TATA box, and contain sequence elements within the 5' flanking 200 bp required for high expression in beta cells [20, 21] . We examined the minimal promoter of the SUR1 gene for sequence variants associated with Type II diabetes and for a possible influence of genetic variants on intravenous glucose and tolbutamide stimulated insulin release.
Subjects and methods
Subjects. Mutation analysis was done using single-stranded conformation polymorphism (SSCP) combined with heteroduplex analysis on genomic DNA from 15 glucose tolerant subjects and 46 unrelated Type II diabetic patients. Seven of the control subjects and 30 of the Type II diabetic patients were known heterozygous carriers of an ACC®ACT, Thr759Thr variant and a c®t intron variant in position ±3 of the exon 16 splice acceptor site, a genotype combination which has been shown to confer increased risk for diabetes [12] . The subsequent association studies were carried out in 455 unrelated Danish Caucasian Type II diabetic patients recruited from the outpatient clinic at Steno Diabetes Center, Copenhagen and 203 unrelated and glucose tolerant Danish Caucasian control subjects matched for age traced randomly in the Danish Central Population Register and living in the same area of Copenhagen as the Type II diabetic patients. Type II diabetes was diagnosed by 1985 World Health Organization criteria. To elucidate the impact of genetic variation on insulin secretion, phenotype-genotype studies were carried out in the 203 middleaged glucose tolerant subjects from the association study and in 60 families with a Type II diabetic proband. Only families with a Type II diabetic parent, a spouse without known diabetes and four or more offspring were asked to participate, and only data from 233 normal glucose tolerant family members were used for phenotype-genotype studies. The number of participating offspring varied from 2±11 per family. In most families 4 offspring were examined. All participants underwent a standard 75 g OGTT. In addition, all non-diabetic family members underwent a tolbutamide modified, frequently sampled IVGTT within 1 week after the OGTT examination. After a 12 h fast, venous blood samples were drawn in triplicate at ±10, ±5 and 0 min before the IVGTT and at 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 35, 40 , 50, 60, 70, 80, 90, 100, 120, 140, 160 and 180 min for analysis of plasma glucose and serum insulin. At t = 0 min glucose was injected intravenously into the contralateral antecubital vein for 1 min (0.3 g/kg body weight of 50 % glucose). At 20 min, a bolus of 3 mg tolbutamide/kg body weight (Orinase, Upjohn, USA) was injected during 5 s to elicit a secondary beta-cell response. Glucose induced acute serum insulin response [AUCinsulin (0±8 min)] was calculated as the incremental areas under the curves from 0 to 8 min. Tolbutamide induced serum insulin response [AUCinsulin (20±30 min)] was calculated as the incremental areas under the curves 0 to 10 min after tolbutamide injection. All the examined participants were Danish Caucasians by self report. Before participation informed consent was obtained from all study participants. The protocol was approved by the Ethics Committee of Copenhagen and was in accordance with the Helsinki declaration II.
Biochemical variables. The plasma concentration of glucose was analysed by an automated glucose oxidation method (Granutest: Merck, Darmstadt, Germany). For all participants the concentration of specific insulin (excluding des(31,32)-and intact proinsulin) in serum was measured by ELISA and the concentration of serum C-peptide were measured by RIA using Steno Diabetes Center routine methods.
Primary mutation analysis of the promoter region of the SUR1 gene. The minimal promoter region (GenBank accession no. AF053478, position: ±465± + 107 bp) was examined in three segments by combined SSCP and heteroduplex scanning with two different experimental settings as described previously [22] . The segments were amplified using specific primers: segment 1 (258 bp): SUR1.prom-1f: 5'-cag gtg gtg gag cag ggc g-3', SUR1.prom-1r: 5'-aaa gca gcc gtt gtt gag gac-3'; segment 2 (318 bp): SUR1.prom-2f: 5'-ccg gca aca tct ggg agc ac ±3', SUR1.prom-2r: 5'-cag gaa aca gct atg acc ggt tct cgc tgc cgc aga ag-3'; segment 3 (298 bp): SUR1.prom-3f: 5'-tgt aaa acg acg gcc agt a cca cgc cca ggt gaa ctc aca-3', SUR1.prom-3r: 5'-cag gaa aca gct atg acc ccc gac cgg ccc tgc tac-3'. When using Amplitaq polymerase (Perkin Elmer, Calif., USA) (segment 3) PCR conditions were: denaturation at 94 C for 3 min followed by 35 cycles of denaturation at 94 C for 30 s, annealing at 65 C for 30 s and extension at 72 C for 30 s with a final extension at 72 C for 9 min. When using Pfu-polymerase (Stratagene La Jolla, Calif., USA) (segment 1 + 2) PCR conditions were: denaturation at 98 C for 3 min followed by 35 cycles of denaturation at 98 C for 1 min, annealing at 65 C (segment 1)/55 C (segment 2) for 1 min and extension at 72 C for 1 min with a final extension at 72 C for 9 min. All PCR reactions were carried out using a GeneAmp 9600 thermal cycler (Perkin Elmer). PCR amplification was carried out in a volume of 25 Statistics. Fishers exact test was used to test for differences in allele frequencies. For genotype-phenotype studies, normal distribution of the residuals was visually verified and if necessary logarithmically transformed. SAS (ver. 6.12) or Statistical Package of Social Science (SPSS) for Windows, version 9.0 were used for analysis. Analysis of data from middle-aged normal glucose tolerant subjects was done using a generalized linear model, with sex and genotype as fixed factors and BMI and age as covariate factors. Family data were analysed using a variance component model (random effects model), where an extra source of variation is allowed to account for the fact that subjects from the same family might be correlated. The variant of interest and sex were included as fixed variables, BMI and age as covariate factors, and family as a random factor. A p value of less than 0.05 was considered statistically significant.
Results
The SUR1 gene promoter has been examined 465 bp upstream of the ATG site in 61 subjects by SSCP-heteroduplex analysis. We identified an a to t substitution 437 bp upstream of the ATG site. Only two subjects who were known heterozygous carriers of both an ACC®ACT, Thr759Thr variant and a c®t intron variant in position ±3 of the exon 16 splice acceptor site, carried the ±437 a®t polymorphism. The allelic frequency was similar in 455 unrelated Type II diabetic patients (a/a: n = 422; a/t: n = 33; t/t: n = 0) and in 203 glucose tolerant control subjects matched for age (a/a: n = 189; a/t: n = 14; t/t: n = 0) (0. 
Discussion
Several studies have shown associations between various non-functional variants in the SUR1 gene and Type II diabetes or a prediabetic phenotype [11±19]. Linkage disequilibrium with a functional mutation in the coding regions, exon-intron boundaries, or the promoter of the SUR1 gene is a possible explanation for these findings. The entire coding region and the intron-exon boundaries of the SUR1 gene have been screened for mutations in Danish and Japanese subjects [12, 23] . Furthermore, the coding region of the Kir6.2 gene, located 4.5 kb downstream of the SUR1 gene has been examined for mutations [22, 24±26] . Also, the promoter sequencies of both genes except for the minimal promoter of the SUR1 gene have been examined [27] . No variants, however, have been identified which could explain the observed associations of SUR1 polymorphisms to Type II diabetes. Various degrees of linkage disequilibrium with one or more functional mutations in a nearby locus or in unexamined regulatory regions of the SUR1/ Kir6.2 genes are therefore the most likely explanation for the published associations between non-functional variants in the SUR1 gene and Type II diabetes. In this study, the possibility that variation in the minimal promoter of the SUR1 gene might contribute to Type II diabetes susceptibility was evaluated. This region is required for high expressions in beta cells [20, 21] but have not been examined in previous studies due to its high G + C content [27] . To increase the likelihood of identifying a functional variant in linkage disequilibrium with previous identified SUR1 polymorphisms, we screened the promoter in 37 subjects who carried a combination of SUR1 variants, an ACC®ACT, Thr759Thr variant and a c®t intron variant in position ±3 of the exon 16 splice acceptor site, which have been shown to confer increased risk of diabetes among Danish subjects [12] . Furthermore we screened 24 randomly selected subjects for SUR1 promoter mutations. We identified one promoter variant 437 bp upstream of the ATG site. This variant was only identified in two subjects carrying the combination of SUR1 variants conferring increased risk of diabetes. It was not associated with Type II diabetes among Danish Caucasian subjects nor was it associated with altered insulin secretion during an OGTT or a tolbutamide modified IV-GTT. Thus, the previous published data on the association of three different polymorphisms with Type II diabetes in various populations does not seem to be explained by the variation in the minimal promoter of the SUR1 gene. However, as the sample sizes in this study are limited to about 200 glucose tolerant control subjects, 250 glucose tolerant offspring of Type II diabetic parents and 450 Type II diabetic subjects a minor effect of the variant cannot be excluded. Also, variation in the SUR1 minimal promoter could be of importance in the development of diabetes in other ethnic groups. Further studies, including examinations of haplotypes in the region seem necessary in order to identify the single variant or haplotype responsible for diabetes risk. In these analyses the possibility of compound heterozygosity for two different at-risk haplotypes conferring the increased risk for diabetes as recently described for the calpain 10-locus [4] should be considered. 
